NCT05687747View on ClinicalTrials.gov

Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

February 28, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI

68Gallium-FAPI-46 PET/MRI is a novel radioactive diagnostic tracer used with Positron Emission Tomography imaging. It defects Fibroblast Activation Protein positive cancer cells and cancer associated fibroblasts.

Trial Locations (1)

119074

RECRUITING

Robert John Walsh, Singapore

All Listed Sponsors
collaborator

National University of Singapore

OTHER

lead

National University Hospital, Singapore

OTHER